Granted Patent B2

US 12,378,216 · App. 17/439,638 · Granted Aug 5, 2025

Inventors: Benjamin Pelcman (Stockholm, SE); Tore Bengtsson (Vaxholm, SE)

Assignee: ATROGI AB

C07D401/06A61K31/44A61K31/4427A61K31/4439A61K31/444A61K45/06A61P3/10

Abstract

Claims (31)

1. A compound of formula IC′

or a pharmaceutically acceptable salt thereof, wherein:

z represents 1 to 3;

n1 represents 1 to 4

each R 1 independently represents C 1-6 alkyl, C 2-6 alkenyl, or C 2-6 alkynyl each optionally substituted by one or more halo;

any two R 1 groups when attached to the same carbon may form together a 3- to 6-membered ring, which optionally is substituted by one or more groups independently selected from halo, C 1-6 alkyl, C 2-6 alkenyl, and C 2-6 alkynyl each optionally substituted by one more halo;

either

one of R 1x and R 1y represents an R 1 group and the other represents H, or

both of R 1x and R 1y represent an R 1 group;

wherein where one of R 1x and R 1y represents an R 1 group and the other represents H, then

when z represents 1 then mx represents 0 to 6, when z represents 2 then mx represents 0 to 8, and

when z represents 3 then mx represents 0 to 10;

wherein where both of R 1x and R 1y represent an R 1 group, then

when z represents 1 then mx represents 0 to 5, when z represents 2 then mx represents 0 to 7, and

when z represents 3 then mx represents 0 to 9;

each X 1 independently represents, as appropriate, halo, R a , —CN, —N(R b )R c , or —OR d ;

R a represents C 1-6 alkyl, C 2-6 alkenyl, or C 2-6 alkynyl each optionally substituted by one or more groups independently selected from G 1 ;

each R b , R c , and R d independently represents H, C 1-6 alkyl, C 2-6 alkenyl, or C 2-6 alkynyl each optionally substituted by one or more groups independently selected from G 2 ;

or alternatively any of R b and R c may be linked together to form, together with the nitrogen atom to which they are attached, a 4- to 6-membered ring, which ring optionally contains one further heteroatom and which ring optionally is substituted by one or more groups independently selected from halo, C 1-3 alkyl, C 2-3 alkenyl, and C 2-3 alkynyl each optionally substituted by one or more halo and ═O;

G 1 and G 2 represents halo, —CN, —N(R a1 )R b1 , —OR c1 , —S(O) p R d1 , —S(O) q N(R e1 )R f1 or ═O;

each R a1 , R b1 , R c1 , R d1 , R e1 and R f1 independently represents H, or C 1-6 alkyl, C 2-6 alkenyl, or C 2-6 alkynyl each optionally substituted by one or more halo;

or alternatively any of R a1 and R b1 and/or R e1 and R f1 may be linked together to form, together with the nitrogen atom to which they are attached, a 4- to 6-membered ring, which ring optionally contains one further heteroatom and which ring optionally is substituted by one or more groups independently selected from halo, C 1-3 alkyl, C 2-3 alkenyl, and C 2-3 alkynyl each optionally substituted by one or more halo and ═O;

each p independently represents 0, 1 or 2; and

each q independently represents 1 or 2,

wherein alkyl, alkenyl and alkynyl groups may be straight-chain or, when there is a sufficient number of carbon atoms, be branched-chain and/or cyclic or part cyclic.

2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, each X 1 independently represents, as appropriate, halo, R a , —CN, or —OR d .

3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein each R 1 group independently represents C 1-3 alkyl optionally substituted by one or more halo.

4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein mx represents 1 to 2.

5. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein n1 represents 1.

6. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and optionally one or more pharmaceutically acceptable adjuvants, diluents, and/or carriers.

7. The compound of claim 1 , wherein z represents 1 or 2.

Assignments (1)

Priority Claims (1)

Continuity (1)

References Cited (400)